article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

from 2003 to 2006, covering the biotechnology and life-science tools sectors. Regulation of cutaneous malignancy by gammadelta T cells. J Exp Med 198(5):747-755 (2003). Previously, Mr Ho served as a Senior Equity Research Analyst at Bank of America from 2006 to 2009 and an Equity Research Analyst at Piper Jaffray & Co.

Therapies 105
article thumbnail

Zigs & Zags – The Opposite of a Great Idea Can Also be a Great Idea

Perficient: Drug Development

I worked on many projects with them in my early career (2003-2013). At that time, their industry was driven by government regulations and tariffs. A Real-World Personal Example – Zagging to Success A successful “zag” with a great idea doesn’t need to be risky. Atlas Van Lines is in the moving and relocation industry.

Marketing 116
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

FDA Law Blog: Biosimilars

It merely says that “[t]he Hatch-Waxman Act and FDA regulations set forth the criteria for listing patents in the Orange Book” and that “Brand manufacturers are responsible for ensuring their patents are properly listed.” But it is not always clear which types of patents are eligible for listing in the Orange Book.

FDA 105
article thumbnail

New drug boosts foetal haemoglobin to fight sickle cell disease

Drug Target Review

Results of the Multicenter Study of Hydroxyurea in Sickle Cell Anaemia published in the Journal of the American Medical Association in 2003, indicated that the use of hydroxyurea, the only drug approved at the time, reduced mortality as it reduced pain crises and increased foetal haemoglobin.

Disease 80
article thumbnail

The Gig Economy, Nightwork, and Stimulant Use

Common Sense for Drug Policy Blog

Melatonin, the hormone involved in the regulation of our biological clock, is released when we are exposed to daylight. "But working at night is not necessarily good for us.

article thumbnail

Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States

The Pharma Data

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to any securities of Biophytis in any country.

article thumbnail

Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

The Pharma Data

with Xolair since its initial approval in 2003. By reducing free IgE, down-regulating high-affinity IgE receptors and limiting mast cell degranulation, Xolair minimizes the release of mediators throughout the allergic inflammatory cascade. Approximately 460,000 patients have been treated in the U.S. In the U.S., About Xolair.